Close this search box.

Moonwalk: Mapping the methylome to create epigenome editors

ARTICLE | Emerging Company Profile

With CRISPR pioneer Feng Zhang among its founders, Moonwalk aims to control gene expression via epigenetic editing

By Danielle Golovin, Senior Biopharma Analyst

April 10, 2024 11:30 PM UTC

Moonwalk is creating DNA methylome maps of diseased and healthy cells, and applying machine learning to identify epigenetic sites it can target to reprogram gene expression and bring the diseased cells back to a state of health.

Launched in January, Moonwalk Biosciences Inc. joins a series of newcos editing the epigenome to control gene expression without the safety risks associated with cutting DNA. Other biotechs in that list include Chroma Medicine Inc., Epicrispr Biotechnologies Inc., Epigenic Therapeutics Co. Ltd. and Tune Therapeutics Inc.